Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Investment Research • Aug 12, 2026

Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Aug 11, 2026

Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Aug 11, 2026

Delcath: Temporary Headwinds Are Fading While Larger Opportunities Approach

Delcath Systems delivered strong Q2 revenue and earnings, with its shares surging as a result. Q3 seasonality is expected to be less pronounced in 2026, which should mean that Delcath's growth remains robust in the second half of the year. As a result, I expect Delcath's stock to continue performing well in 2026.

Seeking Alpha • Aug 7, 2026

Delcath Systems Q2 Earnings Call Highlights

Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.

MarketBeat • Aug 6, 2026

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025.

Business Wire • Aug 6, 2026

Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver c.

Business Wire • Jul 28, 2026

Delcath Systems to Host Second Quarter 2026 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, August 6, 202.

Business Wire • Jul 23, 2026